Galera Therapeutics, Inc. Common Stock
GRTX
GRTX was delisted on the 3rd of June, 2024.
39 hedge funds and large institutions have $13.7M invested in Galera Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 18 reducing their positions, and 9 closing their positions.
9,075% more call options, than puts
Call options by funds: $367K | Put options by funds: $4K
17% less funds holding
Funds holding: 47 → 39 (-8)
49% less capital invested
Capital invested by funds: $26.9M → $13.7M (-$13.1M)
72% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 18
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$192K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$68.5K |
| 3 |
Citigroup
New York
|
+$19.9K |
| 4 |
VF
Virtu Financial
New York
|
+$3.48K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
+$3.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$337K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$210K |
| 3 |
Belvedere Trading
Chicago,
Illinois
|
-$207K |
| 4 |
Two Sigma Investments
New York
|
-$174K |
| 5 |
Two Sigma Advisers
New York
|
-$170K |
GRTX Hedge Fund Activity: Q2 2022 in Review
39 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Galera Therapeutics, Inc. Common Stock (GRTX) for Q2 2022, worth a combined $13.7M — down 49% from $26.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GRTX and 2 opened new positions — a net loss of 7 holders — while 18 trimmed existing stakes and 5 added.
The largest buyer was Ensign Peak Advisors, adding an estimated $192K. The largest seller was Renaissance Technologies, cutting an estimated $337K.
- 39 institutional investors held Galera Therapeutics, Inc. Common Stock (GRTX) as of Q2 2022, down from 47 in Q1 2022.
- Funds reported $13.7M of Galera Therapeutics, Inc. Common Stock stock for Q2 2022, down 49% quarter-over-quarter.
- 2 funds opened new Galera Therapeutics, Inc. Common Stock positions in Q2 2022 and 9 closed out, a net change of -7 holders.
- The largest Galera Therapeutics, Inc. Common Stock buyer in Q2 2022 was Ensign Peak Advisors, an estimated $192K added.
- The largest Galera Therapeutics, Inc. Common Stock seller in Q2 2022 was Renaissance Technologies, an estimated $337K sold.
Based on aggregated 13F filings for Q2 2022.